Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Reiterates Market perform After Foundation Medicine (FMI) Reports Weak 2016 Guidance
February 24, 2016 9:35 AM ESTLeerink Partners reiterated a Market Perform rating on Foundation Medicine (NASDAQ: FMI), and cut the price target to $15.00 (from $27.00), following the company's 4Q earnings report. FMI reported 4Q revenue of $26.1M, above the Street's $25.1M estimate. 2016 revenue guidance of $110M-$120M was ~10%/6% below consensus at... More
Foundation Medicine (FMI) Tops Q4 EPS by 12c, Offers FY Guidance
February 23, 2016 4:05 PM ESTFoundation Medicine (NASDAQ: FMI) reported Q4 EPS of ($0.55), $0.12 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $25.76 million.
GUIDANCE:
Foundation Medicine sees Q1 2016 revenue of $110-120 million, versus the consensus of... More
